Geron (GERN) Research & Development (2010 - 2026)
Geron (GERN) posted Research & Development of $15.0 million for Q1 2026, up 10.38% sequentially from $13.5 million in Q4 2025, and down 0.81% YoY from $15.1 million in Q1 2025.
Geron (GERN) Research & Development (2010 - 2026) Analysis & Trends
Geron has reported Research & Development for 17 years, with the latest figure at $15.0 million in Q1 2026.
- Quarterly Research & Development fell 0.81% year-over-year to $15.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $71.3 million (down 20.27% YoY) and the FY2025 annual result came in at $71.4 million, down 31.14% from the prior year.
- Research & Development grew to $15.0 million in Q1 2026 per GERN's latest filing, from $13.5 million in the prior quarter.
- Over five years, Research & Development peaked at $35.5 million in Q2 2023 and troughed at $13.5 million in Q4 2025.
- A 5-year average of $24.2 million and a median of $23.4 million in 2024 frame the typical range for Research & Development.
- The sharpest annual moves came in 2023 and 2025: Research & Development soared 72.23% in 2023, then plunged 48.67% in 2025.
- Over 5 years, Research & Development stood at $28.2 million in 2022, then gained by 16.66% to $32.9 million in 2023, then retreated by 28.8% to $23.4 million in 2024, then sank by 42.18% to $13.5 million in 2025, then rose by 10.38% to $15.0 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $15.0 million, $13.5 million, and $21.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Geron | 1.04 Mn | -299.81 Mn | - | 22.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22.03 Mn |
| Mar 31, 2026 | 14.96 Mn |
| Dec 31, 2025 | 13.55 Mn |
| Sep 30, 2025 | 21.07 Mn |
| Jun 30, 2025 | 21.74 Mn |
| Mar 31, 2025 | 15.08 Mn |
| Dec 31, 2024 | 23.43 Mn |
| Sep 30, 2024 | 20.15 Mn |
| Jun 30, 2024 | 30.78 Mn |
| Mar 31, 2024 | 29.37 Mn |
| Dec 31, 2023 | 32.91 Mn |
| Sep 30, 2023 | 29.43 Mn |
| Jun 30, 2023 | 35.49 Mn |
| Mar 31, 2023 | 27.22 Mn |
| Dec 31, 2022 | 28.21 Mn |
| Sep 30, 2022 | 24.60 Mn |
| Jun 30, 2022 | 20.61 Mn |
| Mar 31, 2022 | 22.10 Mn |
| Dec 31, 2021 | 24.15 Mn |
| Sep 30, 2021 | 18.53 Mn |